Insmed Inc (INSM)vsMerus BV (MRUS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MRUS
Merus BV
$90.00
0.00%
HEALTHCARE · Cap: $6.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 971% more annual revenue ($606.42M vs $56.61M). MRUS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MRUS
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 8.8x book value
3.2% revenue growth
0.0% earnings growth
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MRUS
MRUS has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MRUS
The primary concerns for MRUS are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while MRUS is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
MRUS is growing revenue faster at 3.2% — sustainability is the question.
MRUS generates stronger free cash flow (-85M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Merus BV
HEALTHCARE · BIOTECHNOLOGY · USA
Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?